atorvastatin / Generic mfg. - LARVOL DELTA

Towards sustainable pharmaceutical QC: micellar-UPLC strategy for concomitant analysis of a cardiovascular polypill with aniline and salicylic acid impurities. (PubMed, Sci Rep) - "This combination includes four active ingredients: aspirin (ASR), atorvastatin calcium (ATC), metoprolol succinate (MES), and ramipril (RAP). Whiteness and greenness appraisals were performed, affirming the applied approach's friendliness to the environment. The priority of this UPLC approach over the published LC ones is due to using a micellar moving phase, making it more eco-friendly to the environment, and the determination of the aforementioned drugs even in the presence of aniline (toxic impurity) and salicylic acid."

Journal • Cardiovascular • Dyslipidemia • Hypertension • Myocardial Infarction

DELPHI: Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD (clinicaltrials.gov) - P2 | N=21 | Recruiting | Sponsor: Massachusetts Eye and Ear Infirmary | Trial completion date: Jan 2024 ➔ Jan 2028 | Trial primary completion date: Jan 2023 ➔ Apr 2027

Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Aspirin and Atorvastatin Augmentation Treatment in Patients with Major Affective Disorders and Inflammatory Dysregulation: A 12-Week Randomized Placebo-Controlled Study. (PubMed, Acta Neuropsychiatr) - "Aspirin and atorvastatin improved depressive symptoms and overall function in patients with major affective disorders. However, both medications raised TNF-αR1 levels, and only atorvastatin increased sIL-2R levels."

Journal • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Oncology • Psychiatry • CRP • IL2 • TNFA

Contemporary Oral Medication Use and Frequency in Patients with Transthyretin Amyloid Cardiomyopathy. (PubMed, Am J Cardiovasc Drugs) - P3 | "Patients with ATTR-CM take oral medications administered multiple times a day for the treatment of HF and other comorbidities. As a BID medication, acoramidis does not appear to deviate from non-ATTR-CM pharmacotherapy strategies, and is therefore not expected to impose additional burden in a real-world setting. These data suggest that acoramidis may align with and could possibly be incorporated into patients' existing non-ATTR-CM pharmacotherapeutic regimens."

Journal • Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

Natural polyketide enterocin inhibits ASGR1 to enhance cholesterol efflux and regulate hepatic lipid metabolism. (PubMed, Metabolism) - "In HFD-fed LDLR-/- mice, enterocin exhibited lipid-lowering activity comparable or superior to that of the positive controls atorvastatin and GW3965. Notably, enterocin demonstrated no significant effect on intestinal fat absorption, highlighting its targeted activity in hepatic cholesterol metabolism. These findings establish enterocin as a novel therapeutic candidate that uniquely modulates cholesterol homeostasis, offering potential for the treatment of both hypercholesterolemia and metabolic dysfunction-associated fatty liver disease."

Journal • Cardiovascular • Dyslipidemia • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • ABCA1

Effects of atorvastatin on inflammatory markers, lipid profile, liver enzymes, and pulmonary function in patients with lung diseases: a systematic review and meta-analysis of randomized controlled trials. (PubMed, Eur J Med Res) - "Atorvastatin demonstrates anti-inflammatory and lipid-lowering efficacy in pulmonary disease patients, with mild functional respiratory benefits and modest improvements in physical performance. Additional large-scale studies are needed to validate clinical benefits and effective treatment methods."

Journal • Retrospective data • Review • Asthma • Cardiovascular • Chronic Obstructive Pulmonary Disease • Hypertension • Immunology • Infectious Disease • Novel Coronavirus Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • IL6 • TNFA

Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin (clinicaltrials.gov) - P1 | N=32 | Active, not recruiting | Sponsor: Guangdong Raynovent Biotech Co., Ltd

New P1 trial • Genetic Disorders • Obesity

Retail Sales of Drugs for Diabetes, Dyslipidemia, and Hypertension in Chile Under 2 Health Policies. (PubMed, Value Health Reg Issues) - "Despite public-sector policies, retail sales of these drugs increased over time, although growth slowed during the second decade."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Hypertension • Metabolic Disorders

ATORTUB-PK: ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD) (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Obafemi Awolowo University Teaching Hospital | Trial completion date: Dec 2027 ➔ Mar 2028 | Trial primary completion date: Dec 2026 ➔ Mar 2027

Trial completion date • Trial primary completion date • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

ATORTUB-PK: ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD) (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Obafemi Awolowo University Teaching Hospital | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2027 ➔ Dec 2027

Enrollment open • Trial completion date • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Symptomatic right vertebral artery web treated with stent implantation and 6-month angiographic follow-up. (PubMed, BMC Neurol) - "This case highlights that VA web should be considered in patients with unexplained posterior circulation ischemia. Stent implantation may represent an effective treatment option for symptomatic patients refractory to medical therapy; however, the risk of post-procedural restenosis should be recognized. Long-term follow-up and further studies are required to determine optimal management strategies."

Journal • Atherosclerosis • Cardiovascular • Musculoskeletal Diseases

Cholesterol-dependent control of endosomal escape regulates intracellular trafficking of small interfering RNA therapeutics and interactions with small molecule drugs. (PubMed, J Pharmacol Exp Ther) - "Notably, chloroquine, an endosomal escape enhancer, rescues gene silencing under cholesterol-reduced conditions...SIGNIFICANCE STATEMENT: This study uncovers cholesterol as an essential and previously unrecognized determinant of small interfering RNA therapeutic efficacy, acting through annexin A2 to enable endosomal escape, a critical bottleneck in RNA drug delivery. The findings position cholesterol modulation as a viable approach to improve the intracellular delivery and therapeutic effectiveness of RNA-based drugs."

Journal • Metabolic Disorders • ANXA2

V-ACCELERATE: Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction (clinicaltrials.gov) - P4 | N=318 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting

Enrollment closed • Atherosclerosis • Cardiovascular • Dyslipidemia • Myocardial Infarction • APOB

STAT NASH: Statins for the Treatment of NASH (clinicaltrials.gov) - P2 | N=70 | Active, not recruiting | Sponsor: Mayo Clinic | Recruiting ➔ Active, not recruiting

Enrollment closed • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis

Cholesterol Promotes Lung Adenocarcinoma Brain Metastasis by Stabilizing EGFR Protein to Drive EMT, Metabolic Reprogramming, and Premetastatic Niche Formation. (PubMed, Adv Sci (Weinh)) - "The cholesterol-lowering drug atorvastatin reverses these tumor-intrinsic and microenvironmental effects and suppresses LUAD brain metastasis in vivo. Retrospective clinical analyses further show that hypercholesterolemia is associated with shortened survival in LUAD-BM patients, whereas statin use correlates with improved outcomes. These findings identify cholesterol as a functional mediator downstream of lipid-metabolic dysregulation and therapeutic target in LUAD-BM."

Journal • Brain Cancer • Dyslipidemia • Lung Adenocarcinoma • Lung Cancer • Metabolic Disorders • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • CLDN5 • EGFR • JAK1 • STAT6

Effects of polypills on cardiovascular outcomes: Meta-analysis of clinical trials and observational studies. (PubMed, Semergen) - "Polypills were effective in reducing CVRF and CVE, and improved adherence compared to taking the constituent individual drugs separately."

Journal • Observational data • Retrospective data • Cardiovascular

Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial. (PubMed, JAMA) - P2 | "This finding may support the use of atorvastatin in patients with lymphoma at high risk of cardiac dysfunction due to anthracycline use. ClinicalTrials.gov Identifier: NCT02943590."

Clinical • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Malignancies • Lymphoma • Oncology

LDL-C Goal Attainment with Fixed-Dose Ezetimibe and Atorvastatin Versus High-Dose Atorvastatin in Chinese Patients: Subgroup Analysis of a Randomized Trial. (PubMed, Adv Ther) - P3 | "FDCs significantly improved LDL-C goal attainment compared to AS monotherapy in patients with very high ASCVD risk. In the subgroups by age and sex, a higher proportion of patients with uncontrolled hypercholesterolemia attained their LDL-C goals."

Clinical • Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Metabolic Disorders

Surface Plasmon Resonance Sensors Based on the Molecularly Imprinted Technique for Simvastatin Detection. (PubMed, ACS Omega) - "The selectivity of SPR sensors for competitive adsorption of atorvastatin and rosuvastatin was also investigated. After optimizing the experimental studies for SIM determination, SIM determination was also performed in artificial plasma solutions, and the recoveries were calculated to be approximately 99%. The findings indicate that SIM imprinted SPR sensors demonstrate exceptional sensitivity and selectivity along with a remarkably low detection limit for precise target identification."

Journal

Carrier free oral Co-delivery of atorvastatin via baicalein-copper-network for atherosclerosis therapy through senescence reversal and multi-mechanistic synergy. (PubMed, Bioact Mater) - "In ApoE-/- mice, CMA markedly reduced aortic plaque burden and fibrosis, while Cu-MON attenuated key features of AS, including decreased ROS, inflammation, DNA damage, and cellular senescence. The CMA demonstrates high synergistic efficacy and biosafety, offering a novel multi-target oral drug strategy for AS treatment."

Journal • Atherosclerosis • Cardiovascular • Fibrosis • Immunology • Inflammation • APOE

Pharmacokinetic Interaction Between Atorvastatin and Hybutimibe in Healthy Chinese Volunteers. (PubMed, Clin Pharmacol Drug Dev) - "For total hybutimibe, the corresponding values were 120.6 (102.4, 142.0) and 105.7 (97.1, 115.2), respectively. Considering the limited PK changes and good safety profiles of both drugs, the interaction between atorvastatin and hybutimibe will likely have no significant clinical impact."

Clinical • Journal • PK/PD data • Dyslipidemia • Metabolic Disorders

Hippocampal myelin damage contributes to cognitive impairment in a rat model of trigeminal neuropathic pain: neuroprotective and anti-inflammatory effects of atorvastatin. (PubMed, Neurosci Res) - "Inflammatory markers including CD95, CD95L, NF-κB, and IL-1β were elevated in TNP rats and downregulated by atorvastatin. These findings suggest that hippocampal myelin damage may underlie TNP-related cognitive deficits, and atorvastatin may exert neuroprotective effects by mitigating neuroinflammation and myelin injury."

Journal • Preclinical • Alzheimer's Disease • Cognitive Disorders • Immunology • Inflammation • Neuralgia • Pain • FAS • FASLG • IL1B • MBP • NFKB1

Clinical efficacy and mechanism of polyene phosphatidylcholine combined with atorvastatin in treating metabolic associated fatty liver disease. (PubMed, Pak J Pharm Sci) - "PPC combined with ATV is superior to PPC alone in improving the liver function, lipid metabolism, inflammation and liver injury without increasing the adverse reactions. It may represent a safe adjunct strategy in MAFLD management."

Journal • Dyslipidemia • Fibrosis • Gastroenterology • Hepatology • Immunology • Liver Cancer • Liver Cirrhosis • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Oncology • Solid Tumor • NFKB1 • TGFB1

Efficacy of combined atorvastatin and argatroban therapy in acute cerebral infarction. (PubMed, Pak J Pharm Sci) - "Atorvastatin combined with argatroban can effectively improve the cerebral hemodynamics, coagulation and endothelial function and reduce the inflammation in ACI patients, thus exerting a good therapeutic efficacy."

Journal • CNS Disorders • Inflammation • Oncology • CRP • EDN1 • IL6 • TNFA

Gut microbiome-metabolomics integration explores the adjunctive effect of Naoxintong capsule on atorvastatin in ameliorating hyperlipidemia: A randomized controlled pilot study. (PubMed, Phytomedicine) - P4 | "Taken together, our study demonstrates that the addition of NXT to atorvastatin could enhance the therapeutic effect against hyperlipidemia, which might be related to the composition alterations of gut microbiota and changes in plasma metabolite abundances. This study provides a novel perspective for understanding the mechanism of NXT in the combination treatment of hyperlipidemia in clinic. (Trial registration No. ChiCTR2500097533)."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Inflammation • Metabolic Disorders • IL6 • TNFA